Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Provincial Landscape
Snapshot: 2026-09-04
Taiwan Multiple Myeloma Active Trials & Centers
As of 2026-09-04, there are 6 active clinical trials for multiple myeloma hosted across 13 tertiary medical centers in Taiwan (including National Taiwan University Hospital, Taipei Veterans General Hospital, China Medical University Hospital, etc.).
Active Trials
6
Hospitals
13
Therapies
Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents
Participating Medical Centers (13)
National Taiwan University HospitalTaipei Veterans General HospitalChina Medical University HospitalNational Taiwan University HospitalChina Medical University HospitalNational Taiwan University HospitalHualien Tzu Chi Medical CenterKaohsiung Medical University Chung-Ho Memorial HospitalTaichung Veterans General HospitalChang Gung Medical Foundation - Kaohsiung BranchE-DA Cancer HospitalFar Eastern Memorial HospitalNational Cheng Kung University Hospital
Active Studies in Taiwan (6)
Population synthesized by CMDNShowing 8 published English records of 6 registry trials.
Phase IIICTR20262221
RecruitingA Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
Population: Relapsed/refractory
Target: Trispecific antibody targeting BCMA, GPRC5D, and CD3
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center、Shanghai Fourth People's Hospital 等 222 家中心
Phase IIICTR20253414
RecruitingA Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone Versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Population: Relapsed/refractory
Target: Novel monoclonal antibody targeting CD38
Study Sites: The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Tianjin Medical University Cancer Institute & Hospital 等 78 家中心
Phase IICTR20230238
RecruitingA Phase II, open-label, single-arm, multicenter clinical study evaluating the efficacy and safety of BCMA-targeted chimeric antigen receptor T-cell injection (CART-BCMA) in patients with relapsed/refractory multiple myeloma (RRMM)
Population: Relapsed/refractory
Target: BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital、The Affiliated Hospital of Hebei University 等 25 家中心
Phase ICTR20262569
RecruitingA Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of 6MW5311 in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and Multiple Myeloma
Population: Relapsed/refractory
Target: LILRB4 and CD3 bispecific antibody
Study Sites: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University 等 8 家中心
Phase IIICTR20232917
RecruitingA Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Population: Newly diagnosed/Maintenance
Target: Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])
Study Sites: Peking University People's Hospital、Tongji Medical College of Huazhong University of Science and Technology、Qilu Hospital of Shandong University、Jiangsu Province Hospital 等 37 家中心
Phase ICTR20260785
RecruitingA Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC Versus DARZALEX FASPRO Combined with Lenalidomide-Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Population: Newly diagnosed
Target: Recombinant fully human monoclonal antibody targeting CD38
Study Sites: Zhongshan Hospital Affiliated to Fudan University、Peking University Third Hospital、Guangzhou First People's Hospital、The Third Hospital of Hebei Medical University 等 66 家中心
Phase IICTR20261752
RecruitingA Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Population: Multiple myeloma
Target: Trispecific antibody targeting BCMA, CD3, and GPRC5D
Study Sites: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital、Heze Municipal Hospital 等 39 家中心
Phase IIICTR20262035
RecruitingA Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Study of IBI3003 Versus Investigator's Choice of Regimen (DPd or PVd) on the Efficacy and Safety in Participants with Relapsed or Refractory Multiple Myeloma
Population: Relapsed/refractory
Target: GPRC5D/BCMA/CD3 trispecific antibody
Study Sites: Zhongshan Hospital, Fudan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The Affiliated Hospital of Xuzhou Medical University 等 45 家中心